July 29, 2026
9 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Amgen rejects FDA claims of avacopan study manipulation, submits new data
Amgen has submitted new re-adjudication data alongside real-world, post-marketing and meta-analysis studies in support of avacopan, arguing the drug maintains a positive risk-benefit ratio and should remain on the market.In a 104-page document submitted to the FDA and provided to Healio, representatives from Amgen also rejected allegations levied by the FDA that employees of avacopan’s
2,315 words~11 min read
